January 22, 2021 by Chain Drug Review
Accumulus Synergy, Amgen, and Takeda, Astellas, Bristol-Myers Squibb, GSK, Lilly, Pfizer, Roche, Sanofi, the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen)
Leading Headlines, Pharmacy
BURLINGAME, Calif. — Ten of the world’s leading biopharmaceutical companies announced the formation of a new non-profit corporation, Accumulus Synergy, which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a
July 31, 2018 by Chain Drug Review
Amgen, biomanufacturing plan, Governor Gina Raimondo, Tia Bush
Pharmacy, Supplier News
THOUSAND OAKS, Calif. — Amgen announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen’s proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets. “Biologics manufacturing is a complex science and has
June 11, 2018 by Chain Drug Review
Amgen, blood cancer, carfilzomib, Dr. David Reese, Kyprolis
Pharmacy, Supplier News
THOUSAND OAKS, Calif. — Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 Aspire trial to the U.S. Prescribing Information for Kyprolis (carfilzomib). Data added to the label showed that Kyprolis, lenalidomide and dexamethasone (KRd)
May 19, 2018 by Chain Drug Review
Aimovig, Amgen, migraine, migraine prevention, Novartis, Novartis Pharmaceuticals, Paul Hudson
Pharmacy, Supplier News
Basel, SWITZERLAND – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to
December 4, 2017 by Chain Drug Review
Amgen, Anthony Hooper, evolocumab, Repatha, Sean Harper
Pharmacy, Supplier News
THOUSAND OAKS, Calif. — After a priority review of its supplemental Biologics License Application, Amgen has gained approval from the Food and Drug Administration for the cardiovascular drug Repatha. Amgen said Repatha (evolocumab 140 mg/ml injection) is the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.
October 16, 2017 by Chain Drug Review
Amgen, James Robinson, Joaquin Duato, Joseph Jimenez, Olivier Brandicourt, Pharmaceutical Research and Manufacturers of America, PhRMA, Robert Bradway, Stephen Ubl
Pharmacy, Supplier News
WASHINGTON — Pharmaceutical Research and Manufacturers of America (PhRMA) has named Amgen Inc. chairman and chief executive officer Robert Bradway as chairman-elect. Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018. Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO
July 18, 2016 by Chain Drug Review and Chain Drug Review
American Pharmacists Association, Amgen, APhA, APhA Academy of Student Pharmacists, APhA-ASP, APhA-ASP Summer Leadership Institute, Cardinal Health, Rite Aid
Leading Headlines, Pharmacy, Retail News
WASHINGTON — Over the weekend, the American Pharmacists Association (APhA) gave pharmacy students an opportunity for their voices to be heard on Capitol Hill. The APhA Academy of Student Pharmacists (APhA-ASP), supported by Rite Aid, Cardinal Health and Amgen, hosted leadership and professional development programming in Washington, D.C., for 240 pharmacy students. Running Friday to
September 3, 2015 by John Schultz and Chain Drug Review
Amgen, filgrastim, Neupogen, Novartis, Richard Francis, Sandoz, Sandoz One Source, Zarxio
Leading Headlines, Pharmacy, Supplier News
NEW YORK — Sandoz has inaugurated a new era in medicine with the release of Zarxio, the first biosimilar of a biologic drug approved in the United States. The Novartis subsidiary said Thursday that Zarxio — a biosimilar of Amgen Corp.’s oncology drug Neupogen, which boosts white blood cells — would broaden access to an